Articles related to TRIPLE-NEGATIVE BREAST CANCER (TNBC)

Among patients with early-stage triple-negative breast cancer, the addition of pembrolizumab to standard chemotherapy demonstrated a 4.9 percentage point improvement in 5-year overall survival.

Explore the detailed findings of a recent study that highlights the impact of treatment interruptions on survival rates in triple-negative breast cancer patients undergoing adjuvant radiotherapy.

Unfolding the Potentials of Anti-TROP2 ADC Therapy in Triple-Negative Breast Cancer Evolving therapeutic paradigms for triple-negative breast cancer (TNBC) are in focus, as esteemed experts highlight the use of novel anti-TROP2 antibody drug conjugates in an enlightening multidisciplinary tumor board.

There were significant state variations in racial and ethnic disparities in TNBC incidence in this cohort study, with Black women in Delaware, Missouri, Louisiana, and Mississippi having the highest rates among all states and racial and ethnic populations. More research is needed to identify factors contributing to the significant geographic variations in racial and ethnic disparities in TNBC incidence in order to develop effective preventive measures, and social determinants of health contribute to the geographic disparities in TNBC risk, according to the findings.

An earlier analysis of this phase 3 trial of neoadjuvant and adjuvant therapy showed that the addition of pembrolizumab to neoadjuvant chemotherapy resulted in a significantly higher percentage of patients with early triple-negative breast cancer having a pathological complete response (defined as no invasive cancer in the breast and negative nodes) at definitive surgery. The trial’s main findings on event-free survival have not been published.

Early triple-negative breast cancer patients who received pembrolizumab along with neoadjuvant chemotherapy had a significantly higher rate of pathological complete responses than those who received placebo along with neoadjuvant chemotherapy.